Laura Sepp-Lorenzino, Ph.D. leads Research and Early Development at Intellia Therapeutics. Before joining Intellia, Laura was at Vertex, Alnylam, Merck and Memorial Sloan-Kettering. She received her professional degree in Biochemistry from the University of Buenos Aires, Argentina and both her M.S. and Ph.D. in Biochemistry from New York University. Laura is a member of the BOD of Taysha Gene Therapies, the Alliance for Regenerative Medicine and the Oligonucleotide Therapeutics Society, and sits on the SABs of Thermo Fisher Scientific, Zymergen, and the U.K. Nucleic Acid Therapy Accelerator.
Advances in Therapeutic CRISPR/Cas9 Genome Editing
Intellia Therapeutics is a leading clinical-stage genome editing company, developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. Highlights from our clinical programs in vivo and ex vivo will be presented, including the first demonstration of CRISPR knockout in humans.